Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasis
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
SCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assets
SCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today
SCYNEXIS will host a conference call and webcast at 8:30 a.m. EDT today. Conference call and webcast details: Investors dial: (877) 704-4453 or (201) 389-0920
Conference ID: 13729053
Call MeTM Feature: Link
Webcast: Link
A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.
https://finance.yahoo.com/news/gsk-scynexis-announce-exclusive-agreement-110500617.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.